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Abstract
Background: Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients
based on genotype. However, there is little data on the impact of pharmacogenetic test results on patient and
clinician choice of therapy. CYP2D6 testing among tamoxifen users offers a potential test case of the use of
pharmacogenetic testing in the clinic. We evaluated the effect of CYP2D6 testing in clinical practice to determine
whether genotype results affected choice of hormone therapy in a prospective cohort study.
Methods: Women planning to take or currently taking tamoxifen were considered eligible. Participants were
enrolled in an informational session that reviewed the results of studies of CYP2D6 genotype on breast cancer
recurrence. CYP2D6 genotyping was offered to participants using the AmpliChip CYP450 Test. Women were
classified as either poor, intermediate, extensive or ultra-rapid metabolizers. Results were provided to clinicians
without specific treatment recommendations. Follow-up was performed with a structured phone interview 3 to 6
months after testing to evaluate changes in medication.
Results: A total of 245 women were tested and 235 completed the follow-up survey. Six of 13 (46%) women
classified as poor metabolizers reported changing treatment compared with 11 of 218 (5%) classified as
intermediate, extensive or ultra-rapid metabolizers (P < 0.001). There was no difference in treatment choices
between women classified as intermediate and extensive metabolizers. In multi-variate models that adjusted for
age, race/ethnicity, educational status, method of referral into the study, prior knowledge of CYP2D6 testing, the
patients’ CYP2D6 genotype was the only significant factor that predicted a change in therapy (odds ratio 22.8; 95%
confidence interval 5.2 to 98.8). Genetic testing did not affect use of co-medications that interact with CYP2D6.
Conclusions: CYP2D6 genotype testing led to changes in therapy among poor metabolizers, even in the absence
of definitive data that an alternative medicine improved outcomes. Pharmacogenetic testing can affect choice of
therapy, even in the absence of definitive data on clinical impact.
Background
Pharmacogenetics may improve health outcomes by
allowing clinicians to tailor medications to patients’ indi-
vidual genetic profiles. Once the genetic determinants of
drug response are identified, additional work will be
required to translate these findings into practice [1-3].
One major question regarding the implementation of
pharmacogenetic testing is how clinicians will incorpo-
rate the results into practice and whether the genotypic
results will lead to a change in therapy.
Tamoxifen, a selective estrogen receptor modulator,
acts as an estrogen receptor antagonist in breast tissue.
In the adjuvant setting, tamoxifen reduces breast cancer
recurrence [4] and mortality [5,6] among women with
hormone receptor-positive breast cancer. Tamoxifen
also reduces the risk of breast cancer in high risk
women [7]. It is metabolized to 4-hydroxy-N-desmethyl-
tamoxifen, also known as endoxifen [8-10], which is
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bolite of tamoxifen [9-11]. Cytochrome P450 2D6
enzyme (CYP2D6) is the rate-limiting enzyme that con-
verts N-desmethyl-tamoxifen into endoxifen [10,12,13].
The CYP2D6 gene is highly polymorphic and has sev-
eral alleles that decrease or completely abolish its enzy-
matic activity. Several studies suggest that breast cancer
patients on tamoxifen with a ‘poor metabolizer’ pheno-
type (two inactive alleles) [11,14-18] or with two alleles
with reduced enzymatic activity [16,19-24] have a higher
rate of breast cancer recurrence compared to patients
with other phenotypes. Recent retrospective analyses
from two large randomized trials comparing tamoxifen
with aromatase inhibition as treatment for early stage
breast cancer in post-menopausal women demonstrated
no impact of CYP2D6 genotype on outcome [25,26].
Nonetheless, the impact of genotype on the effectiveness
of tamoxifen remains uncertain [11,13-23,27,28].
Although there is considerable controversy regarding
the predictiveness of CYP2D6 genotypes on outcomes,
there are alternatives to tamoxifen treatment. Aromatase
inhibitors (AIs) are considered more effective at redu-
cing breast cancer recurrence than tamoxifen alone in
post-menopausal women with hormone receptor-posi-
tive breast cancer [29-33], although no impact has been
demonstrated on mortality. In pre-menopausal women
with early stage hormone receptor-positive breast can-
cer, tamoxifen with or without ovarian suppression (OS)
remains the preferred treatment for standard adjuvant
therapy since no current data demonstrate improved
outcomes of pre-menopausal women on AIs plus OS
[34,35]. However, OS alone or with AIs in pre-meno-
pausal women may be considered an alternative in pre-
menopausal women who do not tolerate tamoxifen
[35-37]. Therefore, CYP2D6 testing may be considered a
useful test case of the use of pharmacogenetic testing in
the clinic since there are alternative treatments.
We prospectively evaluated the effect of CYP2D6 test-
ing in clinical practice and the impact of providing gen-
otype to practitioners and patients in a prospective
cohort study. Specifically, we recruited women who had
recently started or were considered candidates to start
tamoxifen. They were offered CYP2D6 genotype testing
and results were sent to the participant’s clinician. We
then followed women who underwent testing to deter-
mine whether the genotypes affected choice of therapy.
Materials and methods
Study population
Potential participants included women who were cur-
rently on tamoxifen or who were considered candidates
for tamoxifen, either for treatment or prevention of
breast cancer. Patients were recruited by physician refer-
ral or after receiving a contact letter sent to all patients
from the University of California San Francisco (UCSF)
Breast Oncology Clinic who met eligibility criteria. Parti-
c i p a n t sw e r ee x c l u d e di ft h e yc o u l dn o tg i v ei n f o r m e d
consent or could not participate in the educational ses-
sion due to limited English proficiency. Recruitment
took place between March 2008 and May 2010. Most of
the women, 222, were referred to the study from physi-
cians’ offices. Of these, 15 (7%) did not agree to partici-
pate, leaving 207 (93%) referred women who consented
to the study. Another 194 women were contacted by let-
ter. Of those, 102 (52%) did not respond, 54 (28%) said
they were not interested (n = 34) or not on tamoxifen
(n = 20), leaving 38 (20%) women who were recruited
by letter. Thus, a total of 245 women consented to par-
ticipate in this study. The institutional review board at
UCSF approved the study and all women provided writ-
ten informed consent at study entry.
Study protocol
Prior to attending the educational session, each partici-
pant was required to identify a referring physician. The
referring physician received a short description of the
study and agreed to receive the test result in order for
the patient to be enrolled. After signing informed con-
sent, the women participated in an educational session
conducted by a study physician who used an oral and
slideshow presentation to explain genetic testing in gen-
eral. The study physician also showed slides that
included both positive and negative studies regarding
CYP2D6 genotype and breast cancer recurrence. The
studies discussed included those published prior to
March 2008 when recruitment began. The study physi-
cian explicitly told participants that genetic testing
remains controversial in the medical literature and that
additional studies of the utility of genetic testing on
clinical outcome were underway. The presentation was
approximately 30 to 45 minutes long, including 30 stan-
dardized slides and time for questions and discussion.
Participants were asked to complete pre- and post-ses-
sion questionnaires. CYP2D6 testing was offered to all
participants at the end of the session (see laboratory
protocols) and blood was obtained immediately after the
educational component concluded. Results were released
to the referring clinician 2 to 4 weeks after testing.
Follow-up was performed with a structured phone
interview 3 to 6 months after test results were provided
to physicians and patients to determine whether a
change in medication occurred.
Demographic, breast cancer risk factors and tamoxifen
data collection
The pre- and post-educational session questionnaires
collected the following information: demographics, past
medical history, breast cancer history (including
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medication use, knowledge of genetic testing, and atti-
tudes towards uptaking new technology. Women were
classified as pre-menopausal if they indicated having a
menstrual period in the prior 3 months and no change
in menstrual regularity in the prior year; they were con-
sidered post-menopausal if they had no vaginal bleeding
(amenorrhea) for at least 6 months without other
obvious pathological or physiological cause. Participants
were asked if they were experiencing hot flashes, vaginal
dryness, sleep problems and any other side effects from
tamoxifen. The number, intensity, duration, and severity
of hot flashes were reported in the questionnaire. Sever-
ity of each side effect was rated on a Likert scale with
responses ranging from 1 (mild) to 5 (extremely severe).
Laboratory procedures
If the participant agreed to testing, two 10 cc tubes of
blood were drawn. One tube of blood was used for
genomic DNA extraction that was performed at the
UCSF Clinical Pharmacogenomics Laboratory. DNA was
e x t r a c t e df r o mw h o l eb l o o du s i n gt h eQ i a g e nQ I A a m p
Blood DNA Kit (Frederick, MD, USA). After extraction,
DNA was quantified and stored at -20°C. A second
blood sample was collected in a serum separator tube
and stored at -20°C to measure tamoxifen metabolites,
especially endoxifen levels. Tamoxifen metabolite mea-
surements were not reported to patients or clinicians
since there were no clinical data on their use at the
time the study was conceived and designed.
CYP2D6 genotype
The analysis of CYP2D6 polymorphisms was performed
at the UCSF Clinical Pharmacogenomics Laboratory, a
Clinical Laboratory Improvement Amendments Act
(CLIA)-certified laboratory, using the AmpliChip
CYP450 Test (Roche Molecular Systems, Inc., Branch-
burg, NJ, USA). This test uses the Affymetrix microarray
platform and screens for 27 different alleles of the
CYP2D6 gene (including gene duplications and dele-
tions) and 3 alleles of the CYP2C19 gene. The Ampli-
Chip CYP450 Data Analysis Software was used to infer
the genotype, and to predict the individual’s CYP2D6
enzymatic activity. We classified subjects into four
classes: ultra-rapid metabolizers (UMs), extensive meta-
bolizers (EMs), intermediate metabolizers (IMs), and
poor metabolizers (PMs). The test and assay conditions
for this study followed the manufacturer’si n s t r u c t i o n s
[38]. In approximately 1 to 2% of samples, the test
results in a ‘no genotype’ call, presumably because of a
rare variant not detected by the chip that interferes with
the usual hybridization patterns. In every case of a ‘no
genotype’ result from the AmpliChip, we repeated the
assay at least once to confirm that the result could not
be obtained.
Reporting of results
Clinicians were informed of test results, including the
specific genotype and metabolizing status but no specific
treatment recommendation was provided. Results were
reported with the specific genotype (for example, *1/*4)
and the interpretation of the enzymatic activity as classi-
fied by the AmpliChip CYP450 Test (for example,
‘ultra-rapid metabolizer’, ‘extensive metabolizer’, ‘inter-
mediate metabolizer’,o r‘poor metabolizer’). We used
Table 2 from the AmpliChip package insert for the
assignment of ultra-rapid, extensive, intermediate and
poor CYP2D6 metabolizers. In addition, information
about the effect of metabolizer status on endoxifen
levels and the effect of co-medications was provided
based on a commonly used reference [39]. Clinicians
w e r en o tp r o v i d e ds p e c i f i ci n p u ta b o u tt h er e l a t i o n s h i p
between genotype or metabolizer status and breast can-
cer recurrence because of the controversial nature of
this association. Clinicians were provided with a form
letter to help with informing patients that offered two
possible recommendations: (a) to continue current ther-
apy or (b) to call the clinician and schedule an appoint-
ment to discuss the results. The CYP2C19 genotypes
from the AmpliChip test and endoxifen levels were not
part of the main study and these results were not, there-
fore, reported to attending oncologists.
Clinical follow-up
Three to six months after CYP2D6 testing, a follow-up
questionnaire was administered by a trained research
assistant during a structured telephone interview. This
questionnaire ascertained whether the patients received
the CYP2D6 test result letter and discussed CYP2D6
phenotype status (UM, EM, IM, PM) with their clini-
cian, whether the clinician suggested any change in
medication based on the test result (tamoxifen, AIs, or
any other medication), and what change was suggested.
We also determined whether the patients were still tak-
ing, started taking, or stopped taking tamoxifen since
study participation and what the reason was for any
change in hormone therapy.
Statistical analysis
To evaluate the effect of CYP2D6 testing in clinical
practice and to determine whether reported CYP2D6
phenotype affects change in therapy, we compared the
rate of medication change among women identified as
PM to women identified as UM, EM or IM using Fish-
er’s exact test. In our analysis, data from women with
UM and EM phenotype was combined into one category
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same clinical outcome. All analyses were conducted
with the program STATA (version 10, StataCorp LP,
College Station, TX, USA).
Results
A total of 245 women were enrolled in the study, of
whom 235 (96%) participated in the follow-up survey.
Ten women (4%) did not return letters or telephone
calls and were not included in the analysis of follow-up.
The average age of women enrolled in the study was 47
years (range from 23 to 82; Table 1). Most of the parti-
cipants were Caucasian (68%) and Asian (23%). Thirty-
eight percent of women had other chronic health pro-
blems. Seventy-two percent of women were married.
Educational attainment and income were high; 43% had
completed post-graduate degrees and 44% lived in
households with > $100, 000 income. At the time of
breast cancer diagnosis, 78% (184) were pre-menopausal
and 22% (51) were post-menopausal. Nearly all of the
women enrolled in the study (97%) had either invasive
breast cancer or ductal carcinoma in situ (DCIS) with
the majority (70%) reporting invasive breast cancer.
Sixty-eight percent (166) of women in the study were
taking tamoxifen at the time of enrollment for a median
duration of 5 months (range from 1 to 60). The most
common side effects attributed to tamoxifen were hot
flashes (63%), sleep problems (46%) and vaginal dryness
(37%). Approximately 10% of women (24) in the study
reported taking selective serotonin reuptake inhibitors
(SSRIs), but only one was taking an SSRI considered to
be a strong inhibitor of CYP2D6 (paroxetine). In addi-
tion, eight participants (3%) were taking a moderate to
potent inhibitor, the norepinephrine-dopamine inhibitor
buproprion.
The primary referral method in the study was by a
physician or nurse (80%). The rest of the participants
were either self-referred or referred by a breast cancer
support group (4%) or recruited by the study contact
letter (16%). Approximately 50% (122) of the women in
the study had previous knowledge of CYP2D6 testing
and the main source of this knowledge was a physician
or nurse (38%). Other sources of prior knowledge
regarding testing included women who reported reading
about CYP2D6 in the medical literature (20%), the inter-
net (14%), and television or newspapers (5%).
Table 2 shows the detailed CYP2D6 genotypes and
predicted phenotype frequency distribution of partici-
pants in the study by ethnicity. Of the 245 participants,
4% (10) were UMs, 76% (185) were EMs, 13% (32) IMs
and 5% (13) were PMs. In addition, in four of the
women (2%), we could not ascertain the genotype based
on the AmpliChip result (Table 2). Of the 13 PMs, 10
(77%) were Caucasian, 2 (15%) were Latina and 1 (8%)
was Asian. There was no significant difference in the
rate of PMs across these racial/ethnic categories. Of the
32 IMs, 15 (47%) were Asian, 15 were Caucasian and 2
( 6 % )w e r eL a t i n a .A s i a n sw e r em o r el i k e l yt ob ec l a s s i -
fied as IMs compared to Caucasians (P =0 . 0 0 2 ) .O u to f
166 women taking tamoxifen at the time of enrollment,
5 were UMs, 125 EMs, 24 IMs, 7 PMs and 5 ‘no
genotype’.
We found a significant association between CYP2D6
phenotype results and change in therapy (Table 3). Six
of the 13 PMs (46%) changed treatment to an AI, com-
pared to 10 out of 186 in the UM/EM group (P <
0.001). In contrast, there was no significant difference in
treatment change rates between the women classified as
I M s ,1( 3 % ,p r e - m e n o p a u s a l )o u to f3 2 ,a n dU M s / E M s
(P = 0.51). In addition, all four women with ‘no geno-
type’ call were taking tamoxifen at the time of follow-
up, which was no different than the proportion of
women taking tamoxifen among UMs/EMs.
Among the subset of pre-menopausal women (n =
183), 5 of 11 women with the PM phenotype switched
to an AI and OS, which was significantly higher (P =
0.001) than the rate of change among the UMs/EMs (5
of 149). There was no difference among women with
t h eU M / E Mv e r s u sI Mp h e n o t y p ew h e nw ea n a l y z e d
the pre-menopausal women (P = 0.54).
A total of 26 women reported that they were not tak-
ing hormone therapy at the time of follow-up. Of these
women, four (three EMs and one IM, all pre-menopau-
sal) were considering tamoxifen for prevention, seven
(six EMs and one IM) were considering tamoxifen for
treatment of DCIS and six (five EMs and one IM) for
treatment of invasive breast cancer. There was no differ-
ence in the probability of being on or off hormone ther-
apy by CYP2D6 metabolizer status.
Of the 186 UMs/EMs, 21% (38) were taking one or
more co-medications at the time of enrollment. Nine of
these 38 women (24%) changed or stopped a co-medica-
tion at the time of follow-up. Of the women on the
most potent inhibitors, two of nine stopped a co-medi-
cation. There was no significant difference in the rate of
change of co-medication between IMs compared to
UMs/EMs (P = 0.62). None of the PMs were taking any
of the co-medications and CYP2D6 inhibitors described
in Table 1.
We also evaluated whether any factors besides
CYP2D6 genotype predict change in therapy (Table 4).
In univariate analyses there was no association between
change to AIs and method of referral or previous
knowledge of CYP2D6 testing. Among women who said
they had prior knowledge, the source of knowledge
(physician versus medical literature versus internet) did
not affect choice of therapy. We also found no associa-
tion between change in therapy and report of interest in
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in the study
Characteristics (N = 245) N/mean Percent/SD
Mean age (years)
a 47.46 ± 9.7
Self-report ethnicity
Caucasian 166 67.76
Asian/East Asian 56 22.86
African American/Black 2 0.82
Latina/Hispanic 14 5.71
Pacific Islander 1 0.41
Other/mixed 3 1.22
Declined/refused/do not know 3 1.22
Number married (yes) 176 72
Number full-time working 98 40
Education levels
High school graduated or less 6 2.45
Some college 36 14.69
College graduated 90 36.73
Completed post-graduate degree 105 42.86
Declined/refused 8 3.27
Socio-economic status
Income < $50, 000 29 11.84
Income ≥$50, 000 to < $100, 000 56 22.86
Income ≥$100, 000 108 44.07
Declined/refused 52 21.23
Reported other health problems 91 38
Breast cancer characteristics
Breast cancer (yes) 237 97
Had invasive breast cancer 165 70
Surgery (yes) 231 98
Had lumpectomy 119 52
Menopausal status at diagnosis
Pre-menopausal 184 78
Post-menopausal 51 22
Mean age at menopause (years)
a 45.61 ± 6.79
Had natural menopause 35 22.73
Menopause due to chemotherapy treatment 74 48.05
Previous used of hormone therapy 37 15
Tamoxifen use
Ever prescribed 191 78
Ever taken 171 70
Currently taking 166 68
Common side effects attributed to tamoxifen
Hot flashes 154 63
Sleep problems 113 46
Vaginal dryness 90 37
Co-medications/CYP2D6 inhibitors
Strong inhibitors
Paroxetine 1 0.41
Bupropion 8 3.26
Moderate inhibitors
Sertraline 8 3.26
Duloxetine 3 1.22
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medical treatments and technology (P = 0.59). In addi-
tion, age, race/ethnicity and education were not predic-
tive of change in therapy (results not shown). No other
significant associations were found. Specifically, age,
menopausal status, educational attainment, race/ethni-
city and indication for treatment (invasive cancer versus
carcinoma in situ versus prevention) did not predict
change in therapy in univariate analyses. There was no
association between change in hormone therapy and
reported side effects from tamoxifen.
We used multi-variate models to determine whether
any factors may confound the association between
CYP2D6 genotype and change in therapy (Table 4).
CYP2D6 genotype remained the only statistically signifi-
cant association with change in therapy even after
adjustment for age, breast cancer type (invasive breast
cancer, DCIS and lobular carcinoma in situ (LCIS)),
menopausal status (pre-menopausal versus post-meno-
pausal), report of any tamoxifen-induced side effects,
previous knowledge of CYP2D6 testing, referral method
(physician or nurse versus other sources) and interest in
CYP2D6 testing.
Discussion
We provided CYP2D6 genotype results to clinicians and
patients and evaluated the impact of this information on
the proportion of women who changed hormone ther-
apy. Approximately 5% of women were PMs and 6 out
of 13 (46%) changed treatment after discussion with
their physicians. This was a significantly higher percen-
tage than the rate of therapy change in those with UM,
EM or IM phenotypes, suggesting that in this setting
phenotype results affected treatment decisions. The
association between medication change was not con-
founded by method of referral to the study or by prior
interest in CYP2D6 testing.
For pre-menopausal women, change in hormone ther-
apy included both an AI as well as ovarian suppression
that leads to significant side effects associated with early
Table 1 Demographics, breast cancer, tamoxifen use and co-medications use characteristics in the overall population
in the study (Continued)
All other inhibitors
Amitriptyline 2 0.82
Amlodipine 2 0.82
Celecoxib 2 0.82
Ceterizine 2 0.82
Citalopram 6 2.45
Diphenhydramine 3 1.22
Escitalopram 6 2.45
Imipramine 1 0.41
Loratadine 3 1.22
Nortriptyline 1 0.41
Ranitidine 1 0.41
Other co-medications
Gabapentin 10 4.00
Trazodone 2 0.82
Venlafaxine 15 6.12
Referral method
Physician/nurse referral 196 80
Self-referred or breast cancer support group referral 11 4
Study contact letter 38 16
Previous knowledge of CYP2D6 testing (yes) 122 50
Source of CYP2D6 testing knowledge
Physician or nurse 46 38
Newspaper 54
Television 11
Internet 17 14
Medical literature 24 20
Other 27 22
Unknown/missed 2 1
aData presented as mean ± SD. N, number of participants in the study; SD, standard deviation.
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Ethnicity
CYP2D6 predicted phenotype/
genotype
Caucasian Latina/
Hispanic
AA/
Black
Asian Pacific
Islander
Other/
mixed
Declined/
missed
Total N
(%)
Ultra-rapid (UM) 8 (5%) 1 (7%) 0 1 (2%) 0 0 0 10 (4%)
*1/*1 × N 5 0 0 0 0 0 0 5
*1/*2 × N 1 1 0 0 0 0 0 2
*2/*1 × N 1 0 0 1 0 0 0 2
*2/*2 × N 1 0 0 0 0 0 0 1
Extensive (EM) 131
(79%)
9 (65%) 2
(100%)
36
(64%)
1 (100%) 3 (100%) 3 (100%) 185 (76%)
*1/*1 19 2 1 2 1 1 0 26
*1/*2 20 0 0 5 0 0 0 25
*1/*3 2 0 0 0 0 0 0 2
*1/*4 23 1 0 1 0 0 1 26
*1/*5 3 0 0 1 0 1 0 5
*1/*6 1 0 0 0 0 0 0 1
*1/*9 4 2 0 0 0 0 0 6
*1/*10 1 0 0 15 0 0 0 16
*1/*17 1 0 1 0 0 0 0 2
*1/*29 0 0 0 0 0 0 1 1
*1/*35 2 0 0 0 0 0 0 2
*1/*41 16 1 0 1 0 0 0 18
*1 × N/*5 1 0 0 0 0 0 0 1
*1 × N/*10 0 0 0 1 0 0 0 1
*2/*2 5 0 0 0 0 0 0 5
*2/*4 11 1 0 0 0 0 1 13
*2/*5 1 0 0 0 0 0 0 1
*2/*9 1 0 0 0 0 0 0 1
*2/*10 0 1 0 10 0 0 0 11
*2/*35 3 0 0 0 0 0 0 3
*2/*41 5 0 0 0 0 0 0 5
*2/*41 × N 1 0 0 0 0 0 0 1
*2 × N/*4 1 0 0 0 0 0 0 1
*2 × N/*9 1 0 0 0 0 0 0 1
*3/*35 1 0 0 0 0 0 0 1
*4/*35 5 0 0 0 0 0 0 5
*5/*35 0 1 0 0 0 0 0 1
*10/*35 1 0 0 0 0 0 0 1
*17/*35 0 0 0 0 0 1 0 1
*35/*41 1 0 0 0 0 0 0 1
*35/*41 × N 1 0 0 0 0 0 0 1
Intermediate (IM) 15 (9%) 2 (14%) 0 15
(27%)
0 0 0 32 (13%)
*4/*9 1 0 0 0 0 0 0 1
*4/*10 2 0 0 0 0 0 0 2
*4/*17 1 0 0 0 0 0 0 1
*4/*41 6 1 0 0 0 0 0 7
*5/*10 1 0 0 2 0 0 0 3
*10/*10 0 0 0 13 0 0 0 13
*10/*41 2 0 0 0 0 0 0 2
*29/*41 0 1 0 0 0 0 0 1
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risk of side effects from an alternative treatment, physi-
cians and patients frequently changed therapy in
response to a PM phenotype. Treatment with an AI
alone in younger women who have amenorrhea due to
chemotherapy may lead to inadequate hormonal sup-
pression [40]. We did not directly make any treatment
recommendations. But five of the six women who had
changed to an AI also received OS. The only woman
who received AI alone was aged 56 years and was
known to be post-menopausal prior to breast cancer
treatment. Therefore, the physicians who referred to our
study appear to be aware of the risks of inadequate hor-
monal therapy and to have used combination therapy
when appropriate.
The association between CYP2D6 genotype and effi-
cacy of tamoxifen in women with early stage, hormone
receptor-positive breast cancer remains unclear.
CYP2D6 activity clearly correlates with endoxifen levels,
but the association with outcome has been far more
controversial. Several studies have demonstrated an
association [11,14-19], but other studies, including the
two largest, have failed to confirm an impact of enzyme
activity and breast cancer outcome [20-23,25,26]. A
recent meta-analysis found a trend towards association
between CYP2D6 genotype and disease free survival but
not overall survival [41]. However, the authors noted
considerable heterogeneity among the studies in both
the reported associations and in the way subsets of gen-
otypes were grouped. More recently, two large rando-
mized controlled trials, the Arimidex, Tamoxifen, Alone
or in Combination (ATAC) trial [25] and the Breast
International Group (BIG) 1-98 trial [26], evaluated the
impact of CYP2D6 polymorphisms in patients treated
with tamoxifen. Neither study demonstrated an associa-
tion between the risk of breast cancer recurrence and
CYP2D6 phenotype.
Our study had completed all the enrollment and the
follow-up by September 2010, prior to the presentation
of the genotyping data from the ATAC and BIG 1-98
trials in December 2010. Thus, at the time that patients
and clinicians were deciding how to interpret the geno-
types, these results could not be taken into considera-
tion, but could have a significant impact on decisions
regarding testing and treatment change. However, as
part of our presentation to patients prior to testing, we
showed the results of both prior positive and negative
studies testing for associations between CYP2D6 and
breast cancer. Since physicians and patients were aware
of the controversial results, our study demonstrates that
many clinicians and patients are generally willing to
make treatment decisions even in the curative setting
Table 2 Distribution of CYP2D6 genotype and predicted phenotype by different ethnic groups (Continued)
*41/*41 2 0 0 0 0 0 0 2
Poor (PM) 10 (6%) 2 (14%) 0 1 (2%) 0 0 0 13 (5%)
*3/*4 1 0 0 0 0 0 0 1
*4/*4 7 0 0 1 0 0 0 8
*4/*5 0 2 0 0 0 0 0 2
*4/*6 1 0 0 0 0 0 0 1
*4/*7 1 0 0 0 0 0 0 1
No genotype 2 (1%) 0 0 3 (5%) 0 0 0 5 (2%)
Total 166 14 2 56 1 3 3 245
AA, African American; EM, extensive metabolizer; IM, intermediate metabolizer; N, number of participants in the study; PM, poor metabolizer; UM, ultra-rapid
metabolizer.
Table 3 Association of CYP2D6 testing and therapeutic decision-making by CYP2D6 phenotypes
CYP2D6 phenotype Still on
tamoxifen
Changed to
AIs
No
therapy
Total P
a Taking co-
medications
Changed co-
medication
P
a
Ultra-rapid (UM)/extensive
metabolizer (EM)
b
156 (84%) 10 (5%) 20 (11%) 186 38 (21%) 9 (5%)
Intermediate metabolizer (IM) 28 (88%) 1 (3%) 3 (9%) 32 0.51 8 (25%) 2 (3%) 0.62
Poor metabolizer (PM) 4 (31%) 6 (46%) 3 (23%) 13 <
0.001
00 -
Total 188 17 26 231 46 11
aP-value based on Fisher’s exact test of association versus UM/EM.
bUltra-rapid metabolizer (UM) data combined with extensive metabolizer (EM) data. AI,
aromatase inhibitor.
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netic information when accompanied by a reasonable
hypothesis.
T h ep r e v a l e n c eo fCYP2D6 polymorphisms varies
across ethnic groups. The frequency of CYP2D6 PMs in
our study is consistent with previous reports [15,19].
Like other investigators [14,24,42], we found that the
most frequent variant present in Asians was
CYP2D6*10, an allele with reduced activity. Results
examining the association between the *10 allele and
clinical outcomes have also been mixed
[14,16,19,20,24,42]. The rate of medication change
among patients with the IM CYP2D6 phenotype, includ-
ing patients homozygous for this allele, was similar to
that in patients with the UM/EM phenotype, suggesting
that physicians do not consider these patients at signifi-
cantly increased risk of recurrence.
Endoxifen concentration varies not only according to
the number of functional CYP2D6 alleles [43] but also
i nt h ep r e s e n c eo fp o t e n tCYP2D6 enzyme inhibitors.
Agents such as the SSRIs paroxetine or fluoxetine, and
the anti-arrhythmic quinidine are among the most
potent inhibitors [9,44]. When these medications are co-
administered with tamoxifen to women with an EM
phenotype, endoxifen concentrations are similar to
those observed in PM and have the potential, therefore,
to reduce tamoxifen efficacy [9,43,44]. Other commonly
used medications such as buproprion, duloxetine, clomi-
pramine, thioridazine, pherphenazine, and pimozide
exhibit inhibition close to that of paroxetine, fluoxetine
and quinidine [44-46]. While we found that some
women did change their co-medications, this was unre-
lated to CYP2D6 genotype. Our study did not collect
enough information from physicians to distinguish
between those two possibilities.
Our study is unique in that, to our knowledge, no
prior pharmacogenetic studies on change in therapy for
CYP2D6 have been previously published. Several studies
have examined the issue of incorporating pharmacoge-
netic data in dosing warfarin [47,48]; however, genetic
testing for warfarin dosing does not involve a change to
a different medication. Several studies have also shown
Table 4 Association of therapeutic decision-making by clinical and breast cancer characteristics, CYP2D6 phenotype,
previous knowledge of CYP2D6 testing, referral method, and interest in CYP2D6 testing
Change to aromatase inhibitors
Unadjusted Adjusted
a
Characteristics OR (95% CI) P-value OR (95% CI) P-value
Age 1.03 (0.98, 1.08) 0.23 1.02 (0.95, 1.10) 0.50
Breast cancer type
Invasive breast cancer --
Ductal carcinoma in situ (DCIS) 1.07 (0.32, 3.48) 0.90 1.33 (0.34, 5.11) 0.67
Lobular carcinoma in situ (LCIS) 0.82 (0.09, 6.76) 0.85 0.44 (0.03, 5.59) 0.53
Post-menopausal status 1.54 (0.51, 4.62) 0.43 1.78 (0.35, 9.08) 0.48
Report of any tamoxifen side effects (yes) 1.09 (0.34, 3.50) 0.87 0.61 (0.16, 2.31) 0.47
CYP2D6 phenotype
UM/EM
b --
IM 0.56 (0.07, 4.59) 0.59 0.38 (0.04, 3.38) 0.38
PM 15.08 (4.26, 53.33)
0.0001
22.85 (5.28, 98.74)
0.0001
Previous knowledge of CYP2D6 testing (yes) 0.88 (0.33, 2.38) 0.81 0.91 (0.29, 2.84) 0.87
Referred by physician or nurse (yes) 0.60 (0.20, 1.81) 0.37 0.36 (0.09, 1.37) 0.13
Very interested in CYP2D6 testing before attending the educational session (versus somewhat and
not really interested)
1.77 (0.49, 6.38) 0.38 3.01 (0.66, 13.65) 0.15
The number of participants followed up was 235.
aOdd ratios adjusted for age, breast cancer type, menopausal status, report of any tamoxifen side effects,
CYP2D6 phenotype, previous knowledge of CYP2D6 testing, referral method, and interest in CYP2D6 testing. P-value ≤ 0.05.
bUltra-rapid metabolizer (UM) data
combined with extensive metabolizer (EM) data. CI, confidence interval; DCIS, ductal carcinoma in situ; EM, extensive metabolizer; IM, intermediate metabolizer;
LCIS, lobular carcinoma in situ; N, number of participants; OR, odds ratio; PM, poor metabolizer; UM, ultra-rapid metabolizer.
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Page 9 of 12that genetic testing for BRCA1/2 leads to selection of
risk-reducing surgeries [49-51], the use of post-meno-
pausal hormone therapy [52], and pre-implantation
genetic diagnosis [53].
Our study also has several important limitations. First,
the evidence for the association between CYP2D6 poly-
morphisms and outcomes remains mixed in the litera-
ture and the availability of the most recent results may
have changed the decisions that patients and providers
in our study made. Second, our sample may have been
biased by referral patterns and by patient participation.
Physicians and patients who are interested in testing
and in changing therapy based on test results may have
been more likely to participate in our study. However,
we found no association between prior knowledge or
interest in CYP2D6 genotype testing and choice of ther-
apy at follow-up. In addition, there were no other signif-
icant predictors within our data. Third, our sample may
not be universally generalizable. Our patients tended to
be mostly Caucasians and Asians, highly educated on
average, with a relatively high income level, and most
were already being followed at a University medical cen-
ter for breast cancer. Furthermore, our study used
patient self-report of medication use rather than chart
review or physician report. However, both patient report
and physician report may have limitations. More studies
should be conducted to determine how genotyping
results would be used in community settings.
Conclusions
Our study demonstrates that CYP2D6 pharmacogenetic
testing led to change in therapy among patients with
genotypes that predicted no CYP2D6 activity. Thus,
clinicians and patients do use pharmacogenetic results
to change therapy, even in the absence of definitive
knowledge about the utility of the pharmacogenetic
result. Ultimately, prospective randomized trials will be
required to demonstrate the impact of treatment change
based on pharmacogenetic testing.
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